He, X., Su, J., Ma, Y., Zhang, W. & Tang, S. A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines. Front. Immunol. 13, 945930 (2022).
Mohammed, I. et al. The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. Hum. Vaccin. Immunother. 18, 2027160 (2022).
Our World in Data. Share of people who received at least one dose of COVID-19 vaccine. https://ourworldindata.org/grapher/share-people-vaccinated-covid (2024).
Zhang, H., Patenaude, B., Jit, M. & Fang, H. Global vaccine coverage and childhood survival estimates: 1990–2019. Bull. World Health Organ. 102, 276–287 (2024).
Institute for Health Metrics and Evaluation. Financing global health 2025: cuts in aid and future outlook. Report no. 978-1-7341306-2-1 (2025).
The Lancet. The Global Fund and the future of global health. Lancet 406, 2509 (2025).
Kim, S. B. et al. Hepatitis E vaccine landscape update 2025. Expert Rev. Vaccines 24, 1–16 (2025).
ECDC. Efficacy, effectiveness and safety of HPV vaccination in women with conisation: a systematic review and meta-analyses. (2024).
Zhang, J. et al. HPV cancer burden by anatomical site, country, and region in 2022. Sci. Rep. 15, 21048 (2025).
World Health Organization. Immunization coverage. https://www.who.int/news-room/fact-sheets/detail/immunization-coverage (2025).
World Health Organization. Percentage of 15 years old girls received the recommended doses of HPV vaccine. World Health Organization Data https://data.who.int/indicators/i/A7398F0/287D1D2 (2025).
Duran, C., Gupta, A., Aririguzo, L., Castillo, N. & Misra, S. M. Review of human papillomavirus vaccination programs in United States schools. Vaccines https://doi.org/10.3390/vaccines13090894 (2025).
Jiamsiri, S. et al. A community intervention effectiveness study of single dose or two doses of bivalent HPV vaccine (CERVARIX) in female school students in Thailand. PLoS ONE 17, e0267294 (2022).
World Health Organization. Human papillomavirus vaccine: WHO position paper (2022 update). Wkly. Epidemiol. Rec. 50, 645–672 (2022).
Barnabas, R. V. et al. Efficacy of single-dose HPV vaccination among young African women. NEJM Evid. 1, EVIDoa2100056 (2022).
World Health Organization. Global market study: meningococcal meningitis vaccines. https://cdn.who.int/media/docs/default-source/immunization/mi4a/who_meningococcal_vaccines_public_summary.pdf?sfvrsn=b3fb96f7_6 (2019).
World Health Organization. Defeating meningitis by 2030: a global road map. IRIS https://iris.who.int/server/api/core/bitstreams/64850fcf-300f-4b54-b234-4ee54924558f/content (2020).
World Health Organization. WHO Immunizaation Data Portal. https://immunizationdata.who.int/global?topic=Vaccination-coverage&location= (2026).
Meningitis Research Foundation. Meningitis progress tracker. https://tracker.meningitis.org/vaccines/ (2026).
Abuzer, S., Hamdan, H. & Charafeddine, J. Paediatric meningitis outbreak in Gaza amid health system collapse. Lancet 406, 689–690 (2025).
Gil, E. Meningitis B in Kent: an outbreak in the shadow of a pandemic. BMJ 392, s547 (2026).
Watkins, D. A. et al. Global, regional, and national burden of rheumatic heart disease, 1990–2015. N. Engl. J. Med. 377, 713–722 (2017).
Rwebembera, J. et al. 2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease. Nat. Rev. Cardiol. 21, 250–263 (2024).
Carapetis, J. R. et al. Acute rheumatic fever and rheumatic heart disease. Nat. Rev. Dis. Primers 2, 15084 (2016).
Massese, M. et al. Epidemiology of group A streptococcal infection: are we ready for a new scenario?. Lancet Microbe 5, 620–621 (2024).
Thacharodi, A. et al. The burden of group A Streptococcus (GAS) infections: the challenge continues in the twenty-first century. iScience 28, 111677 (2025).
Vekemans, J. et al. The path to group A Streptococcus vaccines: World Health Organization research and development technology roadmap and preferred product characteristics. Clin. Infect. Dis. 69, 877–883 (2019).
Walkinshaw, D. R. et al. The Streptococcus pyogenes vaccine landscape. npj Vaccines 8, 16 (2023).
Etti, M. et al. Maternal vaccination: a review of current evidence and recommendations. Am. J. Obstet. Gynecol. 226, 459–474 (2022).
Male, V. & Jones, C. E. Vaccination in pregnancy to protect the newborn. Nat. Rev. Immunol. 25, 649–661 (2025).
Abu-Raya, B. et al. Global perspectives on immunization during pregnancy and priorities for future research and development: an international consensus statement. Front. Immunol. 11, 1282 (2020).
Aranda, S. S. & Polack, F. P. Prevention of pediatric respiratory syncytial virus lower respiratory tract illness: perspectives for the next decade. Front. Immunol. 10, 1006 (2019).
Halasa, N. B. et al. Maternal vaccination and risk of hospitalization for COVID-19 among infants. N. Engl. J. Med. 387, 109–119 (2022).
Bansal, A., Trieu, M. C., Mohn, K. G. I. & Cox, R. J. Safety, immunogenicity, efficacy and effectiveness of inactivated influenza vaccines in healthy pregnant women and children under 5 years: an evidence-based clinical review. Front. Immunol. 12, 744774 (2021).
Fell, D. B. et al. Effectiveness of influenza vaccination during pregnancy against laboratory-confirmed seasonal influenza among infants under 6 months of age in Ontario, Canada. J. Infect. Dis. 230, e80–e92 (2024).
Nunes, M. C. et al. Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial. Lancet HIV 7, e91–e103 (2020).
Omer, S. B. et al. Efficacy, duration of protection, birth outcomes, and infant growth associated with influenza vaccination in pregnancy: a pooled analysis of three randomised controlled trials. Lancet Respir. Med. 8, 597–608 (2020).
Zerbo, O., Modaressi, S., Goddard, K., Fireman, B. & Klein, N. P. Influenza vaccination during pregnancy and infant influenza in the first 6 months of life. Obstet. Gynecol. 146, e36–e42 (2025).
Buchy, P., Badur, S., Kassianos, G., Preiss, S. & Tam, J. S. Vaccinating pregnant women against influenza needs to be a priority for all countries: an expert commentary. Int. J. Infect. Dis. 92, 1–12 (2020).
Li, Y. et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 399, 2047–2064 (2022).
Kampmann, B. et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N. Engl. J. Med. 388, 1451–1464 (2023).
Farag, A., Elkholy, M. K. A., Genidy, A. M. & Eltobgy, A. Safety and efficacy of maternal RSV vaccination: a systematic review and meta-analysis. Clin. Exp. Vaccine Res. 14, 308–324 (2025).
Phijffer, E. W. et al. Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes. Cochrane Database Syst. Rev. 5, CD015134 (2024).
Pérez Marc, G. et al. Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case-control study. Lancet Infect. Dis. 25, 1044–1054 (2025).
Scott, J. et al. Updated evidence for COVID-19, RSV, and influenza vaccines for 2025–2026. N. Engl. J. Med. 393, 2221–2242 (2025).
Williams, T. C. et al. Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study. Lancet Child Adolesc. Health 9, 655–662 (2025).
Aikaterini, N. I., Soldatou, A., Grantzi, G. -C., Vasileios, G. & Fani, L. Determinants of maternal RSV vaccination uptake: a narrative review. Vaccines https://doi.org/10.3390/vaccines14040293 (2026).
Shaaban, F. L. et al. The path to equitable respiratory syncytial virus prevention for infants: challenges and opportunities for global implementation. Lancet Glob. Health 13, e2165–e2174 (2025).
Procter, S. R. et al. Maternal immunisation against Group B Streptococcus: a global analysis of health impact and cost-effectiveness. PLoS Med. 20, e1004068 (2023).
Thorn, N., Karampatsas, K., Le Doare, K. & Heath, P. T. Progress towards a group B streptococcal vaccine – where are we now?. Vaccine 62, 127575 (2025).
Jeasoh, J., Lim, A., Jeharsae, R. & Khurram, H. Spatio-temporal trends in COVID-19 morbidity and mortality due to elderly: a global perspective. Sci. Rep. https://doi.org/10.1038/s41598-026-37968-z (2026).
Singhal, S., Kumar, P., Singh, S., Saha, S. & Dey, A. B. Clinical features and outcomes of COVID-19 in older adults: a systematic review and meta-analysis. BMC Geriatr. 21, 321 (2021).
Ciabattini, A. et al. Vaccination in the elderly: the challenge of immune changes with aging. Semin. Immunol. 40, 83–94 (2018).
Trombetta, C. M., Kistner, O., Montomoli, E., Viviani, S. & Marchi, S. Influenza viruses and vaccines: the role of vaccine effectiveness studies for evaluation of the benefits of influenza vaccines. Vaccines https://doi.org/10.3390/vaccines10050714 (2022).
Bonten, M. J. et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N. Engl. J. Med. 372, 1114–1125 (2015).
Bulkhi, A. et al. Effectiveness of pneumococcal vaccination in reducing hospitalization and mortality among the elderly: a systematic review and meta-analysis. Hum. Vaccin. Immunother. 21, 2561315 (2025).
Lin, J. et al. Effectiveness of the live-attenuated herpes zoster vaccine 2 years after its introduction in Australia. Vaccine 39, 1493–1498 (2021).
Zeevaert, R., Thiry, N., Maertens de Noordhout, C. & Roberfroid, D. Efficacy and safety of the recombinant zoster vaccine: a systematic review and meta-analysis. Vaccine X 15, 100397 (2023).
Payne, A. B. et al. Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. Lancet 404, 1547–1559 (2024).
Surie, D. et al. RSV vaccine effectiveness against hospitalization among US adults 60 years and older. JAMA 332, 1105–1107 (2024).
Tartof, S. Y. et al. Estimated vaccine effectiveness for respiratory syncytial virus-related lower respiratory tract disease. JAMA Netw. Open 7, e2450832 (2024).
Carrico, J. et al. Cost-benefit analysis of vaccination against four preventable diseases in older adults: impact of an aging population. Vaccine 39, 5187–5197 (2021).
Hung, M.-C. et al. Vaccination coverage among adults in the United States, National Health Interview Survey, 2023. CDC https://www.cdc.gov/adultvaxview/publications-resources/adult-vaccination-coverage-2023.html (2026).
Kramarow, E. A. & Elgaddal, N. Vaccinations among adults age 65 and older: United States, 2024. NCHS Data Briefs. CDC Stacks https://doi.org/10.15620/cdc/174631 (2026).
Kriss, J. L. et al. Influenza, COVID-19, and respiratory syncytial virus vaccination coverage among adults – United States, Fall 2024. MMWR Morb. Mortal Wkly Rep. 73, 1044–1051 (2024).
Vaccines Europe. Adult immunisation. VE https://www.vaccineseurope.eu/life-course-immunisation/adult-immunisation/ (2024).
Vilajeliu, A. et al. Global status of adult immunization post COVID-19 pandemic. Vaccines https://doi.org/10.3390/vaccines13040401 (2025).
Goldin, S. et al. Seasonal influenza vaccination: a global review of national policies in 194 WHO member states in 2022. Vaccine 42, 126274 (2024).
OECD. Health at-a-glance 2023. https://www.oecd.org/en/publications/2023/11/health-at-a-glance-2023_e04f8239/full-report/routine-vaccinations_ee5003aa.html (OECD Publishing, 2023).
Barratt, J. Vaccinations for older adults. Bull. World Health Organ. 100, 359 (2022).
Wilkinson, T. et al. Drug prescriptions and dementia incidence: a medication-wide association study of 17000 dementia cases among half a million participants. J. Epidemiol. Commun. Health 76, 223–229 (2022).
Maggi, S. et al. Association between vaccinations and risk of dementia: a systematic review and meta-analysis. Age Ageing https://doi.org/10.1093/ageing/afaf331 (2025).
Bukhbinder, A. S. et al. Risk of Alzheimer’s disease following influenza vaccination: a claims-based cohort study using propensity score matching. J. Alzheimers Dis. 88, 1061–1074 (2022).
Eyting, M. et al. A natural experiment on the effect of herpes zoster vaccination on dementia. Nature 641, 438–446 (2025).
Pomirchy, M. et al. Herpes zoster vaccination and dementia occurrence. JAMA 333, 2083–2092 (2025).
Schnier, C., Janbek, J., Lathe, R. & Haas, J. Reduced dementia incidence after varicella zoster vaccination in Wales 2013–2020. Alzheimers Dement. 8, e12293 (2022).
Xie, M., Eyting, M., Bommer, C., Ahmed, H. & Geldsetzer, P. The effect of shingles vaccination at different stages of the dementia disease course. Cell 188, 7049–7064 (2025).
Polisky, V. et al. Varicella-zoster virus reactivation and the risk of dementia. Nat. Med. 31, 4172–4179 (2025).
Taquet, M., Dercon, Q., Todd, J. A. & Harrison, P. J. The recombinant shingles vaccine is associated with lower risk of dementia. Nat. Med. 30, 2777–2781 (2024).
GBD 2023 Causes of Death Collaborators. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 1811–1872 (2025).
Heller, J. et al. Unmet needs in vaccine development. Nat. Rev. Drug Discov. 24, 660–661 (2025).
Alberer, M. et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 390, 1511–1520 (2017).
Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817–838 (2021).
Pardi, N. & Krammer, F. mRNA vaccines for infectious diseases — advances, challenges and opportunities. Nat. Rev. Drug Discov. 23, 838–861 (2024).
Barnsley, G. et al. Impact of the 100 days mission for vaccines on COVID-19: a mathematical modelling study. Lancet Glob. Health 12, e1764–e1774 (2024).
Aernout, I. et al. Challenges and opportunities in mRNA vaccine development against bacteria. Nat. Microbiol. 10, 1816–1828 (2025).
Excler, J. L., Saville, M., Berkley, S. & Kim, J. H. Vaccine development for emerging infectious diseases. Nat. Med. 27, 591–600 (2021).
Samarasekera, U. CEPI prepares for future pandemics and epidemics. Lancet Infect. Dis. 21, 608 (2021).
Gouglas, D., Christodoulou, M., Plotkin, S. A. & Hatchett, R. CEPI: driving progress toward epidemic preparedness and response. Epidemiol. Rev. 41, 28–33 (2019).
Azizi, A., Manak, M. & Bernasconi, V. The CEPI centralized laboratory network for COVID-19 will help prepare for future outbreaks. Nat. Med. 29, 2684–2685 (2023).
Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17, 1055–1065 (2010).
Plotkin, S. A. & Gilbert, P. B. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. 54, 1615–1617 (2012).
Bergstrom, C., Fischer, N. O., Kubicek-Sutherland, J. Z. & Stromberg, Z. R. mRNA vaccine platforms to prevent bacterial infections. Trends Mol. Med. 30, 524–526 (2024).
Larsen, S. E., Baldwin, S. L. & Coler, R. N. Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?. Int. J. Infect. Dis. 130, S47–S51 (2023).
Kon, E. et al. A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium. Sci. Adv. 9, eadg1036 (2023).
Wang, X. et al. Strong immune responses and protection of PcrV and OprF-I mRNA vaccine candidates against Pseudomonas aeruginosa. npj Vaccines 8, 76 (2023).
Maruggi, G. et al. Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. Vaccine 35, 361–368 (2017).
Cohen, J. ‘Safety signal’ in Moderna’s RSV vaccine studies halts trials of other vaccines for childhood killer. SCIENCEINSIDER https://www.science.org/content/article/safety-signal-moderna-s-rsv-vaccine-studies-halts-trials-other-vaccines-childhood#:~:text=Scientists%20aren’t%20certain%20Moderna’s%20data,and%20abandoned%20development%20of%20the (13 December 2024).
Reuters. Moderna halts development of birth defect vaccine after trial setback. CNBC https://www.cnbc.com/2025/10/22/moderna-halts-development-of-birth-defect-vaccine-after-trial-setback.html (22 October 2025).
Semenzato, L. et al. COVID-19 mRNA vaccination and 4-year all-cause mortality among adults aged 18 to 59 years in France. JAMA Netw. Open 8, e2546822 (2025).
Bozkurt, B., Kamat, I. & Hotez, P. J. Myocarditis with COVID-19 mRNA vaccines. Circulation 144, 471–484 (2021).
Cao, X. et al. Inhibition of CXCL10 and IFN-γ ameliorates myocarditis in preclinical models of SARS-CoV-2 mRNA vaccination. Sci. Transl. Med. 17, eadq0143 (2025).
Deng, L. et al. Surveillance and follow up outcomes of myocarditis after mRNA COVID-19 vaccination in Australia. npj Vaccines 10, 155 (2025).
Bernard, C. et al. First-trimester mRNA COVID-19 vaccination and risk of major congenital anomalies. JAMA Netw. Open 8, e2538039 (2025).
Ciapponi, A. et al. Safety of COVID-19 vaccines during pregnancy: a systematic review and meta-analysis. Vaccine 41, 3688–3700 (2023).
Faksova, K. et al. COVID-19 vaccines and adverse events of special interest: a multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals. Vaccine 42, 2200–2211 (2024).
Black, S., Madhi, S. A. & Rappuoli, R. Artificial intelligence in the development of vaccines for infectious diseases. Lancet Infect. Dis. 26, 221–222 (2026).
Maman, K. et al. The value of childhood combination vaccines: from beliefs to evidence. Hum Vaccin. Immunother. 11, 2132–2141 (2015).
Kurosky, S. K., Davis, K. L. & Krishnarajah, G. Effect of combination vaccines on completion and compliance of childhood vaccinations in the United States. Hum. Vaccin. Immunother. 13, 2494–2502 (2017).
Wallace, A. S. et al. Experiences with provider and parental attitudes and practices regarding the administration of multiple injections during infant vaccination visits: lessons for vaccine introduction. Vaccine 32, 5301–5310 (2014).
Hausdorff, W. P. et al. Facilitating the development of urgently required combination vaccines. Lancet Glob. Health 12, e1059–e1067 (2024).
Ou, B. S., Saouaf, O. M., Baillet, J. & Appel, E. A. Sustained delivery approaches to improving adaptive immune responses. Adv. Drug Deliv. Rev. 187, 114401 (2022).
Ray, S., Puente, A., Steinmetz, N. F. & Pokorski, J. K. Recent advancements in single dose slow-release devices for prophylactic vaccines. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 15, e1832 (2023).
Michels, S. Y., Daley, M. F. & Newcomer, S. R. Completion of multidose vaccine series in early childhood: current challenges and opportunities. Curr. Opin. Infect. Dis. 37, 176–184 (2024).
Choo, J. J. Y., McMillan, C. L. D., Young, P. R. & Muller, D. A. Microarray patches: scratching the surface of vaccine delivery. Expert Rev. Vaccines 22, 937–955 (2023).
Frivold, C. et al. Identification of potential vaccines for use with microarray patches in low- and middle-income countries: an assessment from the Vaccine Innovation Prioritisation Strategy Alliance. Vaccine 55, 126996 (2025).
Makvandi, P., Jamaledin, R., Mofidfar, M., Wang, X. & Moon, T. S. Advances in the development of microarray patches in biomedicine. N. Biotechnol. 86, 25–30 (2025).
Berger, M. N. et al. Immunogenicity, safety, usability and acceptability of microarray patches for vaccination: a systematic review and meta-analysis. BMJ Glob. Health. https://doi.org/10.1136/bmjgh-2023-012247 (2023).
Adigweme, I. et al. A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial. Lancet 403, 1879–1892 (2024).
Prins, M. L. M., Prins, C., de Vries, J. J. C., Visser, L. G. & Roukens, A. H. E. Establishing immunogenicity and safety of needle-free intradermal delivery by nanoporous ceramic skin patch of mRNA SARS-CoV-2 vaccine as a revaccination strategy in healthy volunteers. Virus Res. 334, 199175 (2023).
Zehrung, D. et al. Measles-rubella microarray patches phase III clinical trial framework: proposal and considerations. Vaccines https://doi.org/10.3390/vaccines12111258 (2024).
CEPI. AI projects. https://cepi.net/artificial-intelligence/ai-projects (2026).
Song, J. Y. et al. Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial. EClinicalMedicine 64, 102140 (2023).
Graham, B. S., Gilman, M. S. A. & McLellan, J. S. Structure-based vaccine antigen design. Annu. Rev. Med. 70, 91–104 (2019).
Villanueva-Flores, F., Sanchez-Villamil, J. I. & Garcia-Atutxa, I. AI-driven epitope prediction: a system review, comparative analysis, and practical guide for vaccine development. npj Vaccines 10, 207 (2025).
Black, S., Madhi, S. A. & Rappuoli, R. Artificial intelligence in the development of vaccines for infectious diseases. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(25)00497-9 (2025).
Alexeev, Y. et al. Artificial intelligence for quantum computing. Nat Commun 16, 10829 (2025).
Moni, S. S. et al. Advancements in vaccine adjuvants: the journey from alum to nano formulations. Vaccines https://doi.org/10.3390/vaccines11111704 (2023).
Pulendran, B. P. S. A. & O’Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454–475 (2021).
Querec, T. et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203, 413–424 (2006).
Zhao, T. et al. Vaccine adjuvants: mechanisms and platforms. Signal Transduct. Target. Ther. 8, 283 (2023).
Richmond, P. et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet 397, 682–694 (2021).
Petrovsky, N. Comparative safety of vaccine adjuvants: a summary of current evidence and future needs. Drug Saf. 38, 1059–1074 (2015).
Tavares Da Silva, F., Di Pasquale, A., Yarzabal, J. P. & Garcon, N. Safety assessment of adjuvanted vaccines: methodological considerations. Hum. Vaccin. Immunother. 11, 1814–1824 (2015).
Shattock, A. J. et al. Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization. Lancet 403, 2307–2316 (2024).
Bärnighausen, T., Bloom, D. E., Cafiero-Fonseca, E. T. & O’Brien, J. C. Valuing vaccination. Proc. Natl Acad. Sci. USA 111, 12313–12319 (2014).
Anekwe, T. D., Newell, M. L., Tanser, F., Pillay, D. & Bärnighausen, T. The causal effect of childhood measles vaccination on educational attainment: a mother fixed-effects study in rural South Africa. Vaccine 33, 5020–5026 (2015).
Adair, L. S. & Guilkey, D. K. Age-specific determinants of stunting in Filipino children. J. Nutr. 127, 314–320 (1997).
Bloom, D. E., Canning, D. & Shenoy, E. S. The effect of vaccination on children’s physical and cognitive development in the Philippines. Appl. Econ. 44, 2777–2783 (2012).
Frongillo, E. A., de Onis, M. & Hanson, K. M. Socioeconomic and demographic factors are associated with worldwide patterns of stunting and wasting of children. J. Nutr. 127, 2302–2309 (1997).
Weinberger, D. M., Pitzer, V. E., Regev-Yochay, G., Givon-Lavi, N. & Dagan, R. Association between the decline in pneumococcal disease in unimmunized adults and vaccine-derived protection against colonization in toddlers and preschool-aged children. Am. J. Epidemiol. 188, 160–168 (2019).
Reichert, T. A. et al. The Japanese experience with vaccinating schoolchildren against influenza. N. Engl. J. Med. 344, 889–896 (2001).
Flem, E. et al. Indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination: a review. Expert Rev. Vaccines 23, 997–1010 (2024).
Ozawa, S. et al. Return on investment from childhood immunization in low- and middle-income countries, 2011–20. Health Aff. 35, 199–207 (2016).
Sim, S. Y., Watts, E., Constenla, D., Brenzel, L. & Patenaude, B. N. Return on investment from immunization against 10 pathogens in 94 low- and middle-income countries, 2011–30. Health Aff. 39, 1343–1353 (2020).
Fletcher, E. R. Public health spending in low income countries stagnates—out of pocket costs soar. Health Policy Watch https://healthpolicy-watch.news/public-health-spending-in-low-income-countries-stagnates-out-of-pocket-costs-soar/#:~:text=40%20x%2040:%20Only%2040,a%20big%20minus%20as%20well (11 December 2024).
Institute for Health Metrics (IHME). Financing global health 2025: cuts in aid and future outlook. https://www.healthdata.org/sites/default/files/2025-07/FGH_2025_FINAL_incl_Translations_2025.07.31.pdf (IHME, 2025).
Krugman, A. The state of global health funding: August 2025. Think Global Health https://www.thinkglobalhealth.org/article/state-global-health-funding-august-2025 (31 July 2025).
Nordström, A. et al. Four paradigm shifts to shape an agenda for global health reforms. Lancet https://doi.org/10.1016/S0140-6736(25)02634-0 (2026).
Water.org. Achieving sustainable development goal 6. https://water.org/documents/187/2020-11-13_Waterorg_Strategy_Overview.pdf#:~:text=There’s%20a%20gap%20in%20financing%20%E2%80%94%20The,an%20annual%20gap%20of%20nearly%20$85.6%20billion (2020).
Kim, C. L., Agampodi, S., Marks, F., Kim, J. H. & Excler, J. L. Mitigating the effects of climate change on human health with vaccines and vaccinations. Front. Public Health 11, 1252910 (2023).
Bidasso, B. How African governments responded to the 2025 aid shock. CGD https://www.cgdev.org/blog/how-african-governments-responded-2025-aid-shock (10 February 2025).
Africa CDC. The African vaccine manufacturing accelerator is a boon for the continent. https://africacdc.org/news-item/the-african-vaccine-manufacturing-accelerator-is-a-boon-for-the-continent/ (28 June 2024).
Gouglas, D. et al. Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. Lancet Glob. Health 6, e1386–e1396 (2018).
Plotkin, S., Robinson, J. M., Cunningham, G., Iqbal, R. & Larsen, S. The complexity and cost of vaccine manufacturing – an overview. Vaccine 35, 4064–4071 (2017).
Young, R. et al. Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model. Gates Open Res 2, 23 (2018).
Carrico, J. et al. Value of the immunization program for children in the 2017 US birth cohort. Pediatrics https://doi.org/10.1542/peds.2021-056007 (2022).
UNICEF. The costs of fully vaccinating a child: countries eligible for Gavi vaccine prices. https://www.unicef.org/media/161751/file/Standard%20costs%20of%20fully%20vaccinating%20a%20child_UNICEF_2024.pdf.pdf (2024).
Frasch, C. E., Preziosi, M. P. & LaForce, F. M. Development of a group A meningococcal conjugate vaccine, MenAfriVac. Hum. Vaccin. Immunother. 8, 715–724 (2012).
Odevall, L. et al. The Euvichol story – development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships. Vaccine 36, 6606–6614 (2018).
Ekwebelem, O. C. et al. COVID-19 vaccination in Africa: a case of unsatisfied expectation and ill-preparedness. Vaccine X 12, 100234 (2022).
Ferranna, M. Causes and costs of global COVID-19 vaccine inequity. Semin. Immunopathol. 45, 469–480 (2024).
Doua, J., Ndembi, N., Auerbach, J., Kaseya, J. & Zumla, A. Advancing local manufacturing capacities for vaccines within Africa – opportunities, priorities and challenges. Vaccine 50, 126829 (2025).
Mwila, C. et al. Operationalizing African self-reliance in vaccine manufacturing. Glob. Health Action 18, 2560209 (2025).
Ndembi, N. & Foláyan, M. O. A regional approach to addressing global health inequities. Lancet 405, 297–298 (2025).
Nkengasong, J. N., Ndembi, N., Tshangela, A. & Raji, T. COVID-19 vaccines: how to ensure Africa has access. Nature 586, 197–199 (2020).
Dzau, V. et al. The time for regionalised vaccine manufacturing has arrived. Lancet 405, 280–282 (2025).
Bednarski, L., Roscoe, S., Blome, C. & Schleper, M. C. Geopolitical disruptions in global supply chains: a state-of-the-art review. Prod. Plann. Control 36, 536–562 (2025).
World Health Organization. The mRNA vaccine technology transfer programme. https://www.who.int/initiatives/mrna-technology-transfer-(mrna-tt)-programme (2025).
ASEAN. ASEAN Leaders’ Declaration on ASEAN Vaccine Security and Self-Reliance (AVSSR). https://asean.org/wp-content/uploads/2019/11/7-ASEAN-Leaders-Declaration-on-ASEAN-Vaccine-Security-and-Self-Reliance-AVSSR.pdf (2 November 2019).
Pan American Health Organization. PAHO announces technology transfer agreement in Argentina to strengthen regional production of seasonal influenza vaccines. PAHO https://www.paho.org/en/news/6-3-2026-paho-announces-technology-transfer-agreement-argentina-strengthen-regional-production (6 March 2026).
GAVI. Gavi outlines plans for African Vaccine Manufacturing Accelerator. https://www.gavi.org/news/media-room/gavi-outlines-plans-african-vaccine-manufacturing-accelerator (2023).
Kaseya, J. et al. The need for locally manufactured health commodities in Africa. Lancet 407, 1140–1141 (2026).
Shadlen, K. C. Accelerating pooled licensing of medicines to enhance global production and equitable access. Lancet 400, 632–634 (2022).
de Beer, J. & De Koker, R. Negotiation of new international health law on intellectual property, technology transfer, open science and pathogen access and benefit sharing: a textual and contextual analysis. BMJ Public Health 2, e001467 (2024).
Larson, H. J. Defining and measuring vaccine hesitancy. Nat. Hum. Behav. 6, 1609–1610 (2022).
Troiano, G. & Nardi, A. Vaccine hesitancy in the era of COVID-19. Public Health 194, 245–251 (2021).
Drobniewski, F. et al. Determinants of vaccine hesitancy among healthcare workers in an international multicenter study within the EuCARE project. Sci. Rep. 15, 31703 (2025).
Motlhale, M., Wilson, K., Jones, D., Chin, G. & Naicker, N. Factors associated with COVID-19 vaccine acceptance among medical laboratory workers in South Africa. J. Public Health Afr. 16, 1291 (2025).
Liu, B. et al. Global vaccine confidence trends among adults above and below age 65. npj Vaccines 10, 160 (2025).
Wiegand, M. et al. Global declines in vaccine confidence from 2015 to 2022: a large-scale retrospective analysis. SSRN https://ssrn.com/abstract=4438003 (2023).
Adeoye, A. F. et al. The 2025 United States measles crisis: when vaccine hesitancy meets reality. Cureus 17, e88196 (2025).
Edwards, K. M., Hackell, J. M. Committee on Infectious Diseases & Committee on Practice and Ambulatory Medicine. Countering vaccine hesitancy. Pediatrics https://doi.org/10.1542/peds.2016-2146 (2016).
Lo Moro, G. et al. Countering vaccine hesitancy: a systematic review of interventions to strengthen healthcare professionals’ action. Eur. J. Public Health 33, 905–915 (2023).
World Health Organization. Global childhood vaccination coverage holds steady, yet over 14 million infants remain unvaccinated—WHO, UNICEF. https://www.who.int/news/item/15-07-2025-global-childhood-vaccination-coverage-holds-steady-yet-over-14-million-infants-remain-unvaccinated-who-unicef (15 July 2025).
Zegeye, A. F. et al. Number of tetanus toxoid injections before birth and associated factors among pregnant women in low and middle income countries: negative binomial poisson regression. Hum. Vaccin. Immunother. 20, 2352905 (2024).
Taye, B. A., Weldearegay, B. Y., Yirsaw, B. G. & Belete, A. K. Tetanus toxoid vaccination coverage and associated factors among pregnant women in East Africa: systematic review and meta-analysis. BMC Public Health 25, 3319 (2025).
Baissas, T. et al. Vaccination in pregnancy against pertussis and seasonal influenza: key learnings and components from high-performing vaccine programmes in three countries: the United Kingdom, the United States and Spain. BMC Public Health 21, 2182 (2021).
Palache, A. et al. Vaccine complacency and dose distribution inequities limit the benefits of seasonal influenza vaccination, despite a positive trend in use. Vaccine 39, 6081–6087 (2021).
O’Neill, J. Tackling drug-resistant infections globally: final report and recommendations. Review on Antimicrobial Resistance https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf (2016).
Tadesse, B. T. et al. Vaccination to reduce antimicrobial resistance burden-data gaps and future research. Clin. Infect. Dis. 77, S597–S607 (2023).
von Gottberg, A. et al. Effects of vaccination on invasive pneumococcal disease in South Africa. N. Engl. J. Med. 371, 1889–1899 (2014).
Yousafzai, M. T. et al. Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study. Lancet Glob. Health 9, e1154–e1162 (2021).
Lewnard, J. A., Lo, N. C., Arinaminpathy, N., Frost, I. & Laxminarayan, R. Childhood vaccines and antibiotic use in low- and middle-income countries. Nature 581, 94–99 (2020).
